Gilead Sciences, Inc. (GILD) Earnings History
Annual and quarterly earnings data from 1990 to 2024
Loading earnings history...
EPS Growth Rates (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | 78.3% | 5.8% | 1.7% |
| 2023 | 76.0% | 28.0% | 20.9% |
| 2022 | 79.3% | 26.9% | 16.8% |
| 2021 | 75.8% | 36.3% | 22.8% |
| 2020 | 81.5% | 16.5% | 0.5% |
Download Data
Export GILD earnings history in CSV or JSON format
Free sign-in required to download data
Gilead Sciences, Inc. (GILD) Earnings Overview
As of March 2, 2026, Gilead Sciences, Inc. (GILD) reported trailing twelve-month net income of $8.51B, reflecting -0.9% year-over-year growth. The company earned $6.79 per diluted share over the past four quarters, with a net profit margin of 0.0%.
Looking at the long-term picture, GILD's 5-year EPS compound annual growth rate (CAGR) stands at -38.2%, signaling declining earnings. The company achieved its highest annual net income of $18.11B in fiscal 2015.
Gilead Sciences, Inc. maintains positive profitability with a gross margin of 0.8%, operating margin of 0.1%, and net margin of 0.0%. The company continues to generate positive earnings from operations. View revenue history →
Compared to industry peers including ABBV ($2.39B net income, 0.1% margin), AMGN ($7.71B net income, 0.2% margin), NVO ($98.50B net income, 0.3% margin), GILD has room to improve margins relative to the peer group. Compare GILD vs ABBV →
Peer Comparison
Earnings metrics vs industry competitors
Historical Data
34 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $480M | -91.5% | $1.66B | $0.38 | 1.7% | 5.8% |
| 2023 | $5.67B | +23.4% | $7.61B | $4.50 | 20.9% | 28.0% |
| 2022 | $4.59B | -26.2% | $7.33B | $3.64 | 16.8% | 26.9% |
| 2021 | $6.22B | +4961.0% | $9.92B | $4.93 | 22.8% | 36.3% |
| 2020 | $123M | -97.7% | $4.07B | $0.10 | 0.5% | 16.5% |
| 2019 | $5.39B | -1.3% | $4.29B | $4.22 | 24.0% | 19.1% |
| 2018 | $5.46B | +17.9% | $8.20B | $4.17 | 24.7% | 37.1% |
| 2017 | $4.63B | -65.7% | $14.12B | $3.51 | 17.7% | 54.1% |
| 2016 | $13.50B | -25.4% | $17.63B | $9.94 | 44.4% | 58.0% |
| 2015 | $18.11B | +49.6% | $22.19B | $11.91 | 55.5% | 68.0% |
See GILD's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs GILD Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare GILD vs AGIO
See how GILD stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is GILD growing earnings?
GILD EPS of $6.79 reflects slowing growth at -0.9%, below the 5-year CAGR of -38.2%. TTM net income is $8.5B. Expansion rate has moderated.
What are GILD's profit margins?
Gilead Sciences, Inc. net margin is +0.0%, with operating margin at +0.1%. Below-average margins reflect competitive or cost pressures.
How consistent are GILD's earnings?
GILD earnings data spans 1990-2024. The current earnings trend is -0.9% YoY. Historical data enables comparison across business cycles.